These findings suggest distinct renal phenotypes of responseliraglutide favoring albuminuria improvement and dulaglutide showing more stable filtration ratesunderscoring the potential for individualized selection based on predominant renal trajectory (proteinuria-dominant vs eGFR-decline phenotype)
Whilst injectable GLP-1 therapies such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are well established in UK clinical practice, transdermal patch formulations represent an emerging area of pharmaceutical development
This is similar to whats reported in FDA data, which shows the most common side effect, nausea, happens in 44% of people on Wegovy (compared to 16% of people on a placebo)
Mild side effects, such as nausea, bloating, constipation, and tiredness, can also happen at the beginning
Several additional compounds deserve mention for anyone planning their long-term strategy